###### Strengths and limitations of this study

-   This study systematically reviews the published evidence for dermoscopy use by primary care physicians in primary care settings, including studies of acceptability and cost-effectiveness, as well as diagnostic accuracy studies.

-   The use of a broad search strategy across multiple databases enabled us to identify 23 studies whose findings examine dermoscopy use in primary care clinical practice.

-   The included studies were of varying quality.

-   Due to the heterogeneity of the included papers, we were not able to undertake any meta-analysis; instead, we performed a narrative synthesis.

Introduction {#s1}
============

Worldwide malignant melanoma is the 15th most common cancer.[@R1] Melanoma has one of the fastest rising incidence rates of any cancer, and among white populations incidence has quadrupled over the last 30 years. In the UK this is projected to rise by a further 7% between 2014 and 2035, reflecting increasing exposure to the main risk factor, ultraviolet radiation.[@R2] There were nearly 300 000 new cases of melanoma worldwide in 2018.[@R1]

Primary care (the first point of contact for patients in the healthcare system, usually community-based) can play an important role in improving outcomes for patients with melanoma. More accurate triage of suspicious pigmented skin lesions could lead to more prompt diagnosis of melanoma at earlier stages and improved outcomes, and reduce unnecessary biopsies or referrals. Most people diagnosed with cancer first present in primary care,[@R3] where primary care physicians (PCPs) need to distinguish rare melanomas from common benign lesions using clinical history taking and visual inspection, aided by checklists such as the 7-point checklist as recommended in the 2015 National Institute for Health and Care Excellence guidelines for suspected cancer.[@R4] Various technologies may also have a role in assisting triage of suspicious skin lesions, including mobile phone applications,[@R5] reflectance confocal microscopy,[@R6] optical coherence tomography,[@R7] computer-aided diagnosis,[@R8] high-frequency ultrasound[@R9] and dermoscopy.[@R10]

Dermoscopy (also referred to as dermatoscopy or epiluminescence microscopy) is a non-invasive technique using a hand-held magnifier and incident light, which may be polarised to reduce reflection, to reveal subsurface structures. Dermoscopy performed by trained specialists is more sensitive and specific in classifying skin lesions than clinical examination with the naked eye alone.[@R4] Dermatologists and some international guidelines recommend PCPs use dermoscopy[@R12]; however, when used by untrained or less experienced clinicians, accuracy can be no better than inspection alone,[@R13] and there is a danger of increased excisions, over-referral or false reassurance. It takes time to train clinicians to use dermoscopy, and PCP training dropout rates have been shown to be high.[@R14] For these reasons dermoscopy is not currently recommended for use by PCPs in the UK,[@R4] although it is used routinely by PCPs in Australia,[@R16] which has the highest incidence of melanoma worldwide. Some digital dermoscopy devices exist, a few of which incorporate computer-aided diagnosis, but they are expensive, and while showing better sensitivity even in expert hands many have lower specificity than clinicians alone.[@R17] However, recent research suggests computer-aided diagnostic tools have the potential to exceed the diagnostic performance of dermatologists.[@R18]

A Cochrane review of dermoscopy has recently been published and examines the diagnostic accuracy of dermoscopy, with and without visual inspection, for the detection of cutaneous invasive melanoma and intraepidermal melanocytic variants in adults.[@R19] Our systematic review has a broader aim, focusing on the first presentation of suspicious skin lesions in primary care and whether dermoscopy and dermoscopy-related technologies, with suitable training, can be used accurately and effectively to triage suspicious skin lesions at this point in the healthcare pathway. We considered various types of dermoscopy technologies, including hand-held dermoscopy, computer-aided/digital dermoscopy devices and novel teledermoscopy approaches (ie, referral using electronic dermoscopy images or video). In addition to data on the diagnostic accuracy of dermoscopy, we looked for data on the practical challenges to implementing dermoscopy in primary care, including utility, acceptability to patients and PCPs, training requirements, and cost-effectiveness.

Methods {#s2}
=======

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,[@R20] and the protocol was registered with PROSPERO prior to conducting the review.[@R21] All aspects of the protocol were reviewed by senior faculty from the CanTest Collaborative ([www.cantest.org](www.cantest.org)).

We searched the MEDLINE, EMBASE, Cochrane Central, Cumulative Index to Nursing and Allied Health Literature, and SCOPUS databases using keywords related to dermoscopy, melanoma and primary care, without language restrictions, from 1 January 1990 to 31 December 2017. We also manually searched the reference lists of included studies. We included all types of study design as we anticipated that there would be few relevant randomised controlled trials (RCTs) or diagnostic accuracy studies performed in primary care, and we aimed to find additional qualitative evidence on barriers to the use of dermoscopy which may be found in non-RCT study designs. We chose to start the search from 1990 as this was when the earliest dermoscopy-related research emerged. We considered published evidence from any international healthcare system and whether it could be interpreted and applied to primary care settings, including the extent to which data collected from specialist clinic settings could be applied to the lower-prevalence primary care population.

We included all studies which provide evidence around test accuracy, utility, acceptability to patients and PCPs, training requirements, and cost-effectiveness of dermoscopy modes in primary care, including trials, diagnostic accuracy and acceptability studies. As our interest was in the use of dermoscopy by generalist clinicians, we included all studies reporting PCP use of dermoscopy; studies of secondary care physicians who were not trained in dermoscopy were assessed for the applicability of their study to answer the research question. We excluded studies that were based in any clinical setting other than at the first assessment of suspicious skin lesions, and any studies that were not considered primary studies.

Following duplicate removal, one author (OJ) screened titles and abstracts to identify studies which fitted the inclusion criteria. Of the titles and abstracts 10% were checked by two other authors (LJ and SH), and interassessor reliability was excellent, with disagreement for only 1 out of the 100 papers checked. Any disagreements were discussed by the core research team (OJ, LJ, SH, FMW) and a consensus reached. At least two reviewers (OJ, LJ, SH, MvM, FMW) independently assessed each full-text article for the possibility of inclusion in the review. Any disagreements were resolved by consensus-based discussion.

Data extraction was undertaken by two reviewers independently (OJ, LJ, FMW) and summarised using descriptive tables, discussion and consensus. We chose to extract only reported outcomes from the included papers, without calculating further quantitative measures of diagnostic accuracy from their data, unless already reported. Due to the heterogeneity of the included papers, we were not able to undertake any meta-analysis; instead, we chose to perform a narrative synthesis.

Risk-of-bias assessment was undertaken for each full-text paper by two independent researchers (OJ, LJ) using the Joanna Briggs Institute (JBI) critical appraisal tools.[@R22] These tools incorporate various critical assessments for different study designs, including patient selection, randomisation, data collection and analysis. As assessments for different study designs had varying denominators, the score was converted to a percentage and classified as high, medium and low risk to aid clarity of presentation and interpretation. Although the studies demonstrated a wide range in quality, no studies were excluded based on their risk-of-bias assessment. Full details of our review question, search strategy, inclusion/exclusion criteria, methodology for data extraction, risk-of-bias assessment and outcomes extraction are described in online supplementary [appendices 1 and 2](#SP1){ref-type="supplementary-material"}, as well as a full list of excluded studies (online supplementary [appendix 3](#SP1){ref-type="supplementary-material"}).
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Patient and public involvement {#s2-1}
------------------------------

Our long-standing collaborator, Mrs Margaret Johnson, is a patient advocate. She commented regularly on the study from its conception, including aspects of the research question, outcome measures and study design. There was no patient recruitment required for this study. The results will be disseminated to patient advocates, groups and relevant charities.

Results {#s3}
=======

[Figure 1](#F1){ref-type="fig"} shows the study PRISMA diagram. There were 837 studies identified, of which 349 were duplicates. Ninety-five articles underwent full-text review and 23 met the inclusion criteria.[@R14] These 23 articles reported data relating to 49 769 lesions and 3708 PCPs.

![PRISMA flow diagram for the studies included in the review. CINAHL, Cumulative Index to Nursing and Allied Health Literature; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](bmjopen-2018-027529f01){#F1}

[Table 1](#T1){ref-type="table"} provides a summary of the study characteristics for included studies. We included three RCTs, two sequential intervention trials (SIT), nine diagnostic accuracy studies, two cohort studies, two case series, one case--control study and four PCP surveys. [Table 1](#T1){ref-type="table"} also visually summarises the practitioner and patient populations reported in the studies and highlights the paucity of studies reporting PCPs using dermoscopy with primary care patients (5 out of 16). Studies of teledermoscopy-based referral systems were more frequently set in primary care, with six out of seven studies involving primary care clinicians and primary care patients. Overall, 16 of the 23 papers reported studies of PCPs, but only 11 papers reported studies involving primary care patients.

###### 

Study demographics: patient and practitioner populations

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study details                    Location                              Study type            Practitioners   Patients   Control group   Intervention group   Gender of patients (except where indicated)\   Age of patients (except where indicated) (years), mean (range)                                                                                                                          
                                                                                                                                                               (F/M) (%)                                                                                                                                                                                                                              
  -------------------------------- ------------------------------------- --------------------- --------------- ---------- --------------- -------------------- ---------------------------------------------- ---------------------------------------------------------------- -- -- -- -- ------------------------------------- ---------------------------------------- --------------------------- ------------------------------
  Dermoscopy papers                                                                                                                                                                                                                                                                                                                                                                                   

  Ahmadi *et al* [@R27]            Maastricht/Limburg, The Netherlands   Case series                                                                                                                                                                                                       None                                  Patients from 3 primary care practices   F=57.8                      54.7 (60--79)

  Argenziano *et al* [@R23]        Barcelona, Spain; Naples, Italy       RCT                                                                                                                                                                                                               Naked eye                             Dermoscopy                               C: F=62.4\                  C: 40 (2--90)\
                                                                                                                                                                                                                                                                                                                                                                          I: F=62.3                   I: 41 (3--94)

  Bourne *et al* [@R28]            Brisbane, Australia                   DA study                                                                                                                                                                                                          Clinical assessment and algorithms    BLINCK algorithm                         F=52.2                      58 (30--60)

  Chappuis *et al* [@R38]          4 regions of France                   Survey                                                                                                                                                                                                            None                                  PCPs in France                           GPs: F=42.4                 GPs:\
                                                                                                                                                                                                                                                                                                                                                                                                      \<30=8\
                                                                                                                                                                                                                                                                                                                                                                                                      30--50=169\
                                                                                                                                                                                                                                                                                                                                                                                                      \>50=246

  Koelink *et al* [@R24]           Groningen, The Netherlands            RCT                                                                                                                                                                                                               Naked eye                             Dermoscopy                               C: F=61.6\                  C: 54.7\
                                                                                                                                                                                                                                                                                                                                                                          I: F=68.2                   I: 53.2

  Menzies *et al* [@R29]           USA, Germany and Australia            DA study                                                                                                                                                                                                          Independent clinicians                SolarScan assessment                     NR                          NR

  Menzies *et al* [@R14]           Perth, Australia                      SIT                                                                                                                                                                                                               PCP decision before intervention      Outcome after dermoscopy and SDDI        NR                          NR

  Morris *et al* [@R39]            Florida, USA                          Survey                                                                                                                                                                                                            None                                  PCPs                                     Clinicians: F=41.6          Clinicians: median\
                                                                                                                                                                                                                                                                                                                                                                                                      40--49 years

  Morris *et al* [@R40]            Florida, USA                          Survey                                                                                                                                                                                                            None                                  Practising physicians                    Clinicians: F=34.7          Clinicians:\
                                                                                                                                                                                                                                                                                                                                                                                                      NR

  Pagnanelli *et al* [@R30]        Rome, Italy                           DA study                              \*                                                                                                                                                                          Pretraining                           Post-training                            NR                          NR

  Rogers *et al* [@R31]            New York, USA                         DA study                                                                                                                                                                                                          Histology/expert opinion              Clinicians using 3 algorithms            F=53.3                      Median\
                                                                                                                                                                                                                                                                                                                                                                                                      31--40 years

  Rogers *et al* [@R32]            New York, USA                         DA study                                                                                                                                                                                                          Histology/expert opinion              Clinicians using 3 algorithms            F=53.3                      Median\
                                                                                                                                                                                                                                                                                                                                                                                                      31--40 years

  Rosendahl *et al* [@R43]         Queensland, Australia                 SIT                   †                                                                                                                                                                                           Naked eye                             Dermoscopy images                        F=32.6                      57\
                                                                                                                                                                                                                                                                                                                                                                                                      SD: 17 years

  Rosendahl *et al* [@R25]         Australian SCARD database             Cohort study                                                                                                                                                                                                      Histology diagnosis                   PCP decision                             NR                          NR

  Secker *et al* [@R44]            Leiden, The Netherlands               DA study                                                                                                                                                                                                          PCPs before education                 After education                          F=51.8                      45.2\
                                                                                                                                                                                                                                                                                                                                                                                                      (28--63)

  Westerhoff *et al* [@R33]        Sydney, Australia                     DA study                                                                                                                                                                                                          PCP diagnosis                         PCPs ± dermoscopy ± education            NR                          NR

  Teledermoscopy papers                                                                                                                                                                                                                                                                                                                                                                               

  Börve *et al* [@R34]             Gothenburg, Sweden                    Case--control study                                                                                                                                                                                               Paper-based referrals                 Teledermoscopy referrals                 C: F=57.1\                  C: 61 (18--97)\
                                                                                                                                                                                                                                                                                                                                                                          I: F=61.4                   I: 54 (18--93)

  Ferrándiz *et al* [@R26]         Andalucia, Spain                      RCT                                                                                                                                                                                                               Clinical images                       Clinical and dermoscopy images           C: F=52.88\                 C: 57.33\
                                                                                                                                                                                                                                                                                                                                                                          I: F=62.28                  I: 54.96

  Grimaldi *et al* [@R35]          Siena, Italy                          DA study                                                                                                                                                                                                          Judgement before dermoscopy           Judgement after dermoscopy               NR                          NR

  Livingstone and Solomon[@R41]    Ruislip, UK                           Case series                                                                                                                                                                                                       Expert diagnosis and standard costs   Teledermoscopy referrals                 NR                          NR

  Moreno-Ramirez *et al* [@R36]    Sevilla, Spain                        DA study                                                                                                                                                                                                          Tele\                                 Same patients\                           F=70.5                      38.8 (1--73)
                                                                                                                                                                                                                                                                                           dermatology referrals                 + dermoscopy images                                                  

  Stratton and Loescher[@R42]      Arizona, USA                          Survey                                                                                                                                                                                                            None                                  Nurse practitioners                      Nurse practitioners: F=92   Nurse practitioners:\
                                                                                                                                                                                                                                                                                                                                                                                                      48

  van der Heijden *et al* [@R37]   Amsterdam, The Netherlands            Cohort study                                                                                                                                                                                                      Face-to-face consult ± histology      Teledermoscopy consult (same patients)   F=55                        Median 47 years, 6--84 years
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![](bmjopen-2018-027529ilf01.jpg)Coloured boxes denote that practitioners and patients from these populations were included in the corresponding study

\*Minimal dermoscopy experience, although secondary care physicians.

†Practitioner population not specified.

BLINCK, Benign, Lonely, Irregular, Nervous, Change, Known clues; C, control group; DA, diagnostic accuracy; DPCSCC, dedicated primary care skin cancer clinic; F, female; GP, General Practitioner; I, intervention group; M, male; NR, not reported; PCP, primary care physician; RCT, randomised controlled trial; SCARD, Skin Cancer Audit Research Database; SCP, secondary care physician; SD, Standard Deviation; SDDI, short-term sequential digital dermoscopy imaging; SIT, sequential intervention trial.

[Table 2](#T2){ref-type="table"} summarises the outcome measures of each included study, grouped into accuracy and reliability outcomes and implementation outcomes, and shows the heterogeneous nature of the reported outcomes. The accuracy and reliability outcomes were diverse; 12 papers reported sensitivity and specificity, 8 reported diagnostic accuracy or area under the curve, 5 reported positive and negative predictive values, 14 reported the proportion of correct decisions, 4 reported the number needed to excise, and 5 reported the biopsy rate. The implementation outcomes were less numerous but also quite diverse: 4 papers reported on PCP opinions, 3 performed cost-effective analyses, 2 looked at response times for teledermoscopy services, 2 looked at image quality for teledermoscopy, and 1 assessed patient satisfaction.

###### 

Diversity of reported outcomes and critical appraisal results of the included studies

  Study                                     Accuracy and reliability outcomes   Implementation outcomes   JBI critical appraisal checklists[@R22]                                                     
  ----------------------------------------- ----------------------------------- ------------------------- ----------------------------------------- -- -- -- -- -- -- -- --- -- --- -- -- -- -- -- -- --
  RCTs and sequential intervention trials                                                                                                                                                             
  Argenziano *et al* [@R23]                                                                                                                                                                           
  Koelink *et al* [@R24]                                                                                                                                                                              
  Menzies *et al* [@R14]                                                                                                                                                                              
  Rosendahl *et al* [@R43]                                                                                                                                                                            
  Ferrándiz *et al* [@R26]                                                                                                                                                                            
  Non-RCT diagnostic accuracy studies                                                                                                                                                                 
  Ahmadi *et al* [@R27]                                                                                                                                                                               
  Bourne *et al* [@R28]                                                                                                                                                                               
  Menzies *et al* [@R29]                                                                                                                                                                              
  Pagnanelli *et al* [@R30]                                                                                                                                                                           
  Rogers *et al* [@R31]                                                                                                                                                                               
  Rogers *et al* [@R32]                                                                                                                                                                               
  Rosendahl *et al* [@R25]                                                                                                                                                                            
  Secker *et al* [@R44]                                                                                                                                                                               
  Westerhoff *et al* [@R33]                                                                                                                                                                           
  Börve *et al* [@R34]                                                                                                                                                                                
  Grimaldi *et al* [@R35]                                                                                                                                                                             
  Livingstone and Solomon[@R41]                                                                                                                                                                       
  Moreno-Ramirez *et al* [@R36]                                                                                                                                                                       
  van der Heijden *et al* [@R37]                                                                                                                                                                      
  Survey-based studies                                                                                                                                                                                
  Chappuis *et al* [@R38]                                                                                                                                                                             
  Morris *et al* [@R39]                                                                                                                                                                               
  Morris *et al* [@R40]                                                                                                                                                                               
  Stratton and Loescher[@R42]                                                                                                                                                                         

![](bmjopen-2018-027529ilf06.jpg){#img6}denotes that these accuracy and reliability outcomes were reported in this study; ![](bmjopen-2018-027529ilf05.jpg){#img5}denotes that these implementation outcomes were reported in this study

Key to JBI score: ![](bmjopen-2018-027529ilf01.jpg){#img1}; \>60%: ![](bmjopen-2018-027529ilf02.jpg){#img2}; \<30%: ![](bmjopen-2018-027529ilf03.jpg){#img3}.

AUC, area under the curve; DA, diagnostic accuracy; JBI, Joanna Briggs Institute; NNE, number needed to excise; NPV, negative predictive value;OR, Odds Ratio; PCP, primary care physician; PPV, positive predictive value; RCTs, randomised controlled trials; TDS, teledermoscopy.

Risk-of-bias outcomes from the JBI critical appraisal tools are included in [table 2](#T2){ref-type="table"}, demonstrating a wide range in quality across the studies. No studies were excluded based on the risk-of-bias assessment.

[Tables 3](#T3 T4 T5){ref-type="table"} summarises the diagnostic accuracy results, with the studies grouped into RCTs and SITs, non-RCT diagnostic accuracy studies, and survey studies. Among the RCTs and SITs, Argenziano *et al*,[@R23] Koelink *et al*,[@R24] Rosendahl *et al* [@R43] and Menzies *et al* [@R14] found that dermoscopy reduced the number needed to excise to diagnose a melanoma. Ferrándiz *et al* [@R26] evaluated the impact of adding dermoscopic images to the standard teledermatology referral system and found that it improved accuracy and confidence in diagnosing skin lesions.

###### 

Summarised results of the RCTs and SITs

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Summary                                                                                                                                                                                                        Control (C)/Intervention (I)(number of lesions)        Outcome measures                                                                                                                                                                                                                                                                                                                                                            
  --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------- --------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -----------------
  RCTs and SITs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Argenziano *et al* [@R23]   RCT in primary care comparing PCPs using naked-eye observation (ABCD) with PCPs using dermoscopy (3-point checklist).                                                                                          C (1325)                                               Non-susp=925\                                                     39 susp\                                23 malig\                                                 Sens 54.1%\                                                                                                                                             PPV 11.3% NPV 95.8%                             2/6 MMs missed.
                                                                                                                                                                                                                                                                                                    Susp=408                                                          46 susp                                 30 malig                                                  Spec 71.3%                                                                                                                                                                                              

  I (1203)                    Non-susp=824\                                                                                                                                                                                                  16 susp\                                               6 malig\                                                          Sens 79.2%\                             PPV 16.1% NPV 98.1%                                       1/6 MMs missed.                                                                                                                                                                                         
                              Susp=379                                                                                                                                                                                                       61 susp                                                33 malig                                                          Spec 71.8%                                                                                                                                                                                                                                                                                                

  Koelink *et al* [@R24]      Cluster RCT in primary care comparing PCP diagnosis with naked-eye examination and dermoscopy examination.                                                                                                     C (230)                                                Non-susp=67\                                                      Correctly diagnosed: MMs 22.2% (2/9)\                                                                                                                                                                                                                     All lesions OR=1.51\                            
                                                                                                                                                                                                                                                                                                    Referred=20\                                                      Lesions 40.5% (90/222)                                                                                                                                                                                                                                    Relative risk=1.25\                             
                                                                                                                                                                                                                                                                                                    Biopsy/excision=135                                                                                                                                                                                                                                                                                                         MM OR=5.52                                      

  I (207)                     Non-susp=84\                                                                                                                                                                                                   Correctly diagnosed: MMs 61.5% (8/13)\                                                                                                                                                                                                                                                                                                                                                                                             
                              Referred=18\                                                                                                                                                                                                   Lesions 50.5% (98/194)\                                                                                                                                                                                                                                                                                                                                                                                                            
                              Biopsy/excision=92                                                                                                                                                                                             3 skin cancers incorrectly treated                                                                                                                                                                                                                                                                                                                                                                                                 

  Menzies *et al* [@R14]      SIT using within-lesion controls in primary care assessing effect of dermoscopy and SDDI on management of suspicious PSLs by PCPs.                                                                             C (374)                                                374 PSLs suspicious for referral ± excision                       42 malignant lesions\                   For MM:\                                                  56.4% reduction in suspicious PSLs excised/referred. 63.5% reduction in benign excised PSLs. 1 MM in situ incorrectly managed in intervention group.\                                                   
                                                                                                                                                                                                                                                                                                                                                                      33 MM, 1 MM in situ                     Naked-eye: sens 37.5%, spec 84.6%, PPV 20.7, NPV 92.7     Benign:MM ratio of excised/referred lesions 9.5:1 vs 3.7:1 (after dermoscopy) vs 3.5:1 (dermoscopy + SDDI) (p\<0.0005).                                                                                 

  IA (374)                    After dermoscopy\                                                                                                                                                                                              Dermoscopy: sens 53.1%, spec 89.0%, PPV 34, NPV 94.7                                                                                                                                                                                                                                                                                                                                                                               
                              110 referred, 192 SDDI, 72 observed for change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  IB (192)                    Of 192 SDDI, 46 referred/excised,\                                                                                                                                                                             +SDDI: sens 71.9%, spec 86.6%, PPV 36.4, NPV 96.6                                                                                                                                                                                                                                                                                                                                                                                  
                              6 continued SDDI (2 subsequently referred, 4 observed),\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                              140 observed (5 subsequently referred, 135 observed)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                              Overall:Increased sens for all malignancies (40%--67.5%, p=0.014) and MM (37.5%--71.9%, p=0.006) following intervention.Increased PPV for MM (20.7%--36.4%, p=0.055) and NPV for MM (92.7%--96.6%, p=0.041).                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Rosendahl *et al* [@R43]    SIT using within-lesion controls. Comparison of PSL diagnosis of 'blinded observers' using macroscopic images, then dermoscopy images.                                                                         C (463)                                                Single best diagnosis matched HP diagnosis in 320 cases (69.1%)   29 MMs, 72 BCCs, 5 SCCs\                To achieve 80% spec, 70.5% sens                           AUC 0.83 (malignant neoplasms).\                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                      NB: all PSLs excised                                                                              AUC 0.71 (melanocytic lesions).                                                                                                                                                                         

  I (463)                     Single best diagnosis matched HP diagnosis in 375 cases (80.1%)(p\<0.001)                                                                                                                                      To achieve 80% spec, 82.6% sens (NS)                   AUC 0.89 (malignant neoplasms) (p\<0.001).\                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                    AUC 0.76 (melanocytic lesions) (NS).                                                                                                                                                                                                                                                                                                                                        

  Ferrándiz *et al* [@R26]    RCT comparing DA and cost-effectiveness of clinical teleconsultations with clinical + dermoscopic teleconsultations from 5 primary care centres.                                                               C (226)                                                70.36% non-susp\                                                  2.77% MM, 11.54% non-MM skin cancer     Sens 86.57%\                                              PPV 56.98\                                                                                                                                              False negative rate 13.43%.\                    
                                                                                                                                                                                                                                                                                                    45.14% referred for face-to-face evaluation                                                               Spec 72.33%                                               NPV 92.86\                                                                                                                                              False positive rate 22.16%.\                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Accuracy index 79.20%                                                                                                                                   69.71% decisions made with higher confidence.   

  I (228)                     73.24% non-susp, 20.18% referred for face-to-face evaluation (p\<0.001)                                                                                                                                        2.19% MM, 7.89% non-MM skin cancer                     Sens 92.86%\                                                      PPV 84.38\                              False negative rate 7.14%.\                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                    Spec 96.24%                                                       NPV 98.17\                              False positive rate 3.76%.\                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                      Accuracy index 94.30% (p\<0.001)        78.07% decisions made with higher confidence (p=0.001).                                                                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summarised results of the included non-RCT DA studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Summary                                                                                                                                                                                                 Intervention or group\                                                         Outcome measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                        (number of lesions)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  Non-RCT DA studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Ahmadi *et al* [@R27]                         Retrospective cross-sectional study of medical files from 3 general practices.                                                                                                                          \(580\)                                                                        67 malignant, 75 premalignant, 399 non-suspicious, 39 unknown. 16.7% of patients referred.                                                                                                                                                                                                                                                                       151 lesions confirmed by HP/dermatology: 37 BCC, 4 MMs, 1 lentigo maligna, 20 unknown.                                                                                                                                                                                                                                                                     PPV: benign lesions 85.7%, premalignant lesions 18.2%, malignant lesions 53.8%,\                                                                                                                                                                                                                                                                                                                              Tools used: dermoscopy 8.4%, experienced PCP advice 1.4%, biopsy 1.9%, excision 10.3%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   BCCs 53.3%, melanoma 25%.                                                                                                                                                                                                                                                                                                                                                                                     

  Bourne *et al* [@R28]                         Sequential design DA study. 4 PCPs used new BLINCK dermoscopy algorithm on 50 lesion images, compared with same PCPs using 3-point checklist, Menzies and clinical assessment on same 50 images.        BLINCK (200)                                                                   Found 33/36 MMs.\                                                                                                                                                                                                                                                                                                                                                Images of 50 lesions used: 1 invasive MM (0.52 mm), 8 in situ.                                                                                                                                                                                                                                                                                             Sens 90.8%\                                                                                               DA 65.5%\                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                       Biopsied 131/200 lesions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Spec 50%                                                                                                  Number-needed-to-excise 6                                                                                                                                                                                                                                                                           

  3PCL (200)                                    Found 19/36 MMs.\                                                                                                                                                                                       Sens 59.4%\                                                                    DA 48.3%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                Biopsied 105/200 lesions.                                                                                                                                                                               Spec 42.2%                                                                     Number-needed-to-excise 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Menzies (200)                                 Found 16/36 MMs.\                                                                                                                                                                                       Sens 54.7%\                                                                    DA 63.9%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                Biopsied 71/200 lesions.                                                                                                                                                                                Spec 69%                                                                       Number-needed-to-excise 13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Clinical (200)                                Found 9/36 MMs.\                                                                                                                                                                                        Sens 52.6%\                                                                    DA 65%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                Biopsied 74/200 lesions.                                                                                                                                                                                Spec 74.8%                                                                     Number-needed-to-excise 22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Menzies *et al* [@R29]                        Sequential design DA study comparing the performance of SolarScan with that of clinicians with varying dermatology experience on 78 images of PSLs.                                                     Dermatologist (78)                                                             10.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Diagnosing MM:\                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sens 81%, spec 60%, PPV 30, NPV 94\                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Decision to excise:\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sens 79%, spec 60%, PPV 29, NPV 93                                                                                                                                                                                                                                                                                                                                                                            

  PCP (78)\                                     8                                                                                                                                                                                                                                                                                      Diagnosing MM:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                       Sens 62%, spec 63%, PPV 26, NPV 89\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                       Decision to excise:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                       Sens 62%, spec 61%, PPV 25, NPV 89                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                        SolarScan (78)                                                                 11.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Diagnosing MM: sens 85%, spec 65%, PPV 32, NPV 96\                                                        SolarScan's sensitivity was higher than PCPs but NS.                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Decision to excise: sens 85%, spec 65, PPV 32, NPV 96                                                                                                                                                                                                                                                                                                                                                         

  Pagnanelli *et al* [@R30]                     Sequential design DA study to assess if internet-based course suitable to teach dermoscopy to 16 clinicians with minimal dermoscopy experience looking at 20 images of PSLs.                            Control: pretraining (20)                                                                                                                                                                                                                                                                                                                                                                                                                       20 PSLs in test set: 6 MMs, 14 non-MMs.                                                                                                                                                                                                                                                                                                                    Pattern analysis:\                                                                                        DA 49.8\                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sens 67.7%, spec 76.3%                                                                                    k-intraobserver agreement 0.42                                                                                                                                                                                                                                                                      

  ABCD:\                                        DA 38.8\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Sens 58%, spec 73.4%                          k-intraobserver agreement 0.31                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  7-point checklist:\                           DA 60.2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Sens 100%, spec 67.5%                         k-intraobserver agreement 0.58                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Menzies method:\                              DA 53.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Sens 80.4%, spec 72%                          k-intraobserver agreement 0.50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                        Intervention: post-training (20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Pattern analysis:\                                                                                        DA 60.1\                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sens 82%, spec 78.5%                                                                                      k-intraobserver agreement 0.58                                                                                                                                                                                                                                                                      

  ABCD:\                                        DA 56.6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Sens 78.4%, spec 79.6%                        k-intraobserver agreement 0.55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  7-point checklist:\                           DA 64.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Sens 100%, spec 69.8%                         k-intraobserver agreement 0.61                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Menzies method:\                              DA 62.8\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Sens 93.4%, spec 76%                          k-intraobserver agreement 0.66                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Rogers *et al* [@R31]                         Sequential design DA study examining performance of new TADA when used by 120 clinicians of various specialties looking at 50 PSL images.                                                               \(50\)                                                                         5641 lesion evaluations performed: 3034 malignant, 2607 non-suspicious.                                                                                                                                                                                                                                                                                          50 lesion images in test set, 23 benign, 27 malignant. Sens and spec calculated for malignant lesions.                                                                                                                                                                                                                                                     Dermatologists:\                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sens 94.8%, spec 78.5%                                                                                                                                                                                                                                                                                                                                                                                        

                                                Non-dermatologists:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                Sens 93.7%, spec 72.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                \>1 year dermoscopy experience:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                Sens 95.4%, spec 77.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                \<1 year dermoscopy experience:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                Sens 91.3%, spec 74.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Rogers *et al* [@R32]                         Sequential design DA study comparing performance of new TADA with existing dermoscopy algorithms when used by 120 clinicians of various specialties.                                                    \(50\)                                                                         No data for 3-point checklist and AC rule.\                                                                                                                                                                                                                                                                                                                      50 lesion images in test set, 23 benign, 27 malignant. Sens and spec based on 40 non-PSLs.                                                                                                                                                                                                                                                                 TADA:\                                                                                                    Sens for MM with TADA 94%. Spec for untrained clinicians for benign PSLs using TADA 76%--94% (beginners can be quickly trained to identify benign lesions).                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                       TADA: 5646 lesions evaluated.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sens 94%, spec 75.5%                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                       2056 deemed non-suspicious (1891 true negatives (92.0%), 165 false negatives (8.0%)).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                       3590 deemed malignant (2871 true positives (80.0%), 719 false positives (20.0%)).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                AC:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                Sens 88.6%, spec 78.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                3-point checklist:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                Sens 71.9%, spec 81.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                Untrained (using TADA): Sens 93.6%, spec 69%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                Trained (using TADA):\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                Sens 95.4%, spec 73.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Rosendahl *et al* [@R25]                      Prospective cohort study using SCARD to assess impact of dermoscopy use and subspecialisation on MM diagnosis by PCPs.                                                                                  Dedicated skin cancer practitioners                                            Number of lesions seen not recorded on SCARD.\                                                                                                                                                                                                                                                                                                                   11.7% were MM.                                                                                                                                                                                                                                                                                                                                                                                                                                                       MM number needed to treat: 8.5                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                       11 992 lesions referred.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  PCP with special interest in skin cancer      1942 lesions referred.                                                                                                                                                                                  10.6% MM.                                                                                                                                                                                                                                                                                                                                                                                                                                       MM number needed to treat: 9.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  PCPs                                          1942 lesions referred.                                                                                                                                                                                  5.9% MM.                                                                                                                                                                                                                                                                                                                                                                                                                                        MM number needed to treat: 17.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                        High dermoscopy use                                                            17 917 lesions referred.                                                                                                                                                                                                                                                                                                                                         11.2% MM.                                                                                                                                                                                                                                                                                                                                                                                                                                                            MM number needed to treat: 8.9                                                                                                                                                                                                                                                                      

  Medium use                                    2657 lesions referred.                                                                                                                                                                                  9.1% MM.                                                                                                                                                                                                                                                                                                                                                                                                                                        MM number needed to treat: 10.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Low use                                       1093 lesions referred.                                                                                                                                                                                  6.9% MM.                                                                                                                                                                                                                                                                                                                                                                                                                                        MM number needed to treat: 14.6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (p\<0.0001, but NS when adjusted for subspecialisation)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Secker *et al* [@R44]                         Sequential design DA study comparing performance of 293 PCPs in diagnosing PSLs before and after a training intervention.                                                                               Pretest (clinical images, no education)\                                                                                                                                                                                                                                                                                                                                                                                                        20 PSL images in test set: 3 MM, 2 BCC, 15 benign.                                                                                                                                                                                                                                                                                                         For MM:\                                                                                                  \% correct treatment: (1) malignant 85.87, (2) naevi 92.83, (3) benign 9.56                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                        (20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sens 0.49%, spec 0.75%                                                                                                                                                                                                                                                                                                                                                                                        

  Post-test (clinical images with education)\                                                                                                                                                                                                                                                                                          Sens 0.50%, spec 0.77%                                                                                                                                                                                                                                                                                                                                           \(1\) malignant 84.03, (2) naevi 95.61, (3) benign 7.81                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  (20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                        Integrated\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sens 0.66%, spec 0.70%                                                                                    \(1\) malignant 91.74,(2) naevi 92.35, (3) benign 29.35                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                        post-test (clinical and dermoscopic images with education)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                        (20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Overall                                                                                                                                                                                                                                                                                                                              Training improved sens and spec for all except pigmented naevi. Training improved DA for all PSLs except naevi.                                                                                                                                                                                                                                                  Increase in correct treatments for benign lesions, reduced unnecessary referrals and excisions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Westerhoff *et al* [@R33]                     Intervention study assessing performance of 74 PCPs with no dermoscopy experience in diagnosing 100 PSLs using macroscopic images ± dermoscopy images before and after an educational intervention.     Control:\                                                                                                                                                                                                                                                                                                                                                                                                                                       100 images of lesions used: 50 invasive MMs and 50 non-melanomas.                                                                                                                                                                                                                                                                                          Macroscopic images:\                                                                                      Significant improvement with training between pretest (54.6%) and post-test (62.7%) (p=0.007) on macro images. Diagnosis of MM with dermoscopy significantly better (75.9%) than macro images (62.7%)(p=0.000007). No significant difference adding dermoscopic images in diagnosing non-MM PSLs.   
                                                                                                                                                                                                                                                        no education\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Pretest:\                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                        (100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Sens 50.6%, spec 55.2%\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Post-test:\                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sens 53.7%, spec 51.5%                                                                                                                                                                                                                                                                                                                                                                                        

  +Dermoscopic images:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Pretest:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sens 52.9%, spec 58.1%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Post-test:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Sens 54.8%, spec 55.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Intervention:\                                                                                                                                                                                                                                                                                                                       Macroscopic images:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  with education\                                                                                                                                                                                                                                                                                                                      Pretest:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  (100)                                                                                                                                                                                                                                                                                                                                Sens 54.6%, spec 53.0%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                       Post-test:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                       Sens 62.7%, spec 53.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  +Dermoscopic images:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Pretest:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sens 57.8%, spec 55.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Post-test:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Sens 75.9%, spec 57.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Börve *et al* [@R34]                          Case--control study. Smartphone TDS system in 20 primary healthcare centres compared with traditional, paper-based referral system from other primary healthcare centres.                               Control:\                                                                      746 suspicious lesions referred.                                                                                                                                                                                                                                                                                                                                 323 malignant (13 MM, 7 MM in situ, 22 SCCs, 115 BCCs, 164 AKs), 423 benign.                                                                                                                                                                                                                                                                                                                                                                                         3/4 invasive MMs given medium/low priority, 3/5 MMs in situ given low priority. Mean response time 5 days (range 0--82 days). Patients received primary treatment on single face-to-face visit in 82.2% of cases.                                                                                   
                                                                                                                                                                                                                                                        paper-based referrals\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                        (746)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Intervention:\                                816 suspicious lesions referred. 346 (42%) non-suspicious, final diagnosis benign for 343 (3 malignant lesions missed were AKs). 196 deemed malignant, 146 (74%) also malignant after dermatology/HP.   229 malignant (19 MM, 16 MM in situ, 24 SCCs, 109 BCCs, 61 AKs), 587 benign.                                                                                                                                                                                                                                                                                                                                                                    All invasive MMs prioritised correctly (high), all MM in situ at least medium priority. 22.6% more referrals given low priority. Mean response time 109 min (range 2 min to 46 hours). Waiting time for surgical treatment for MM significantly shorter (p\<0.0001). Patients received primary treatment on single face-to-face visit in 93.4% of cases.                                                                                                                                                                                                                                                                                                                                                                                                                 
  smartphone TDS referrals\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  (816)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Grimaldi *et al* [@R35]                       Sequential design DA study assessing PCP diagnosis of suspicious PSLs before and after dermoscopic evaluation and accuracy of teledermatology triage system.                                            PCP clinical\                                                                  167 lesions non-suspicious, 68 suspicious.                                                                                                                                                                                                                                                                                                                       16 malignant (5 MMs), 219 benign.                                                                                                                                                                                                                                                                                                                          Dermoscopy by PCPs and then experts led to 76.5% reduction in number of surgical procedures (68 to 16).   PCP clinical vs PCP dermoscopy: p\<0.001, OR 0.345731                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                        (235)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  PCP\                                          206 non-suspicious, 29 suspicious (dermoscopy-corrected diagnosis in 57.3% of cases, only 1 false negative).                                                                                            PCP clinical vs expert dermoscopy: p\<0.001, OR 0.179425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  dermoscopy\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  (235)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  TDS\                                          219 non-suspicious, 16 suspicious (1 false negative from 206 benign lesions).                                                                                                                           PCP dermoscopy vs expert dermoscopy: p\<0.05, OR 0.518973                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  (235)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Livingstone and Solomon[@R41]                 Prospective case series to assess cost-effectiveness, accuracy and patient satisfaction of a TDS system for non-malignant PSLs in a primary care practice.                                              \(248\)                                                                        248 patients that PCP would have been referred routinely to dermatology referred to TDS service. 102 needed face-to-face dermatology review. 146 advised on treatment. 3 lesions possibly malignant so referred 2-week-wait pathway.                                                                                                                             0/3 possibly malignant lesions were malignant at face-to-face review. None of other 245 lesions were malignant after review or follow-up.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Waiting time for images to be taken (weeks): 0--1=27%, 1--2=45%, 2--3=7%, 3--4=0%, 4--5=7%, 5--6=7%.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Waiting time for results (weeks): 0--1=14%, 1--2=61%, 2--3=14%, 3--4=7%.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 129 patients returned patient satisfaction questionnaires. 100% said TDS service was explained, 100% would recommend TDS.

  Moreno-Ramirez *et al* [@R36]                 Sequential design DA study to assess if teledermatology with dermoscopy images would improve the current teledermatology-based triage system in referrals from a primary care centre.                   Control: teledermatology referrals\                                            4 BCCs, 1 MM, 0 dysplastic naevus, 56 benign.\                                                                                                                                                                                                                                                                                                                   HP: 2 BCCs, 1 MM, 1 dysplastic naevus, 57 benign.                                                                                                                                                                                                                                                                                                          Sens 1 (as 0 false negative), spec 0.65, false positive rate 0.35                                         Clinical picture quality excellent 41%, poor 3.3%. Average diagnostic confidence 4.14/5. Agreement with histology 0.91.                                                                                                                                                                             
                                                                                                                                                                                                                                                        (61)                                                                           Referral rates 47.5% (29).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                       Rate of referral of true positive results 17.2% (5 true positives/29 referrals).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                       False positives 58.7% (17/29 referrals).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Intervention: TDS referrals\                  2 BCCs, 1 MM, 1 dysplastic naevus, 54 benign.\                                                                                                                                                                                                                                         Sens 1 (as 0 false negatives), spec 0.78 (p\<0.05), false positive rate 0.22 (p\<0.05)                                                                                                                                                                                                                                                                           Dermoscopic picture quality excellent 63.9%, poor 6.6%. Average diagnostic confidence 4.75/5 (p\<0.05). Agreement with histology 0.94.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  (61)                                          Referral rates 39.3% (24) (p\<0.05).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                Rate of referral of true positive results 20.8% (5 true positives/24 referrals) (p\<0.05).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                False positives 41.7% (10/24) (p\<0.05).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  van der Heijden *et al* [@R37]                Cohort study assessing accuracy and reliability of TDS diagnosis with images taken by PCPs compared with diagnosis at face-to-face consultations for same lesions.                                      Control: face-to-face assessment\                                              All 108 lesions also referred for face-to-face assessment. 76 lesions seen face-to-face by dermatology. 32 not seen as did not attend, moved away, GP did excision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Agreement face-to-face vs HP diagnosis k=0.90 (almost perfect), diagnostic agreement k=0.56--0.78 (substantial), management agreement k=0.31--0.38 (fair).                                                                                                                                          
                                                                                                                                                                                                                                                        (76)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                       Agreement TDS vs face-to-face diagnosis k=0.55--0.73 (moderate-substantial), TDS vs face-to-face management k=0.19--0.29 (fair). Image quality: 36% bad, 36% good. TDS consultations with good image quality had better agreement, TDS vs face-to-face diagnosis (k=053--0.77, substantial), and TDS vs face-to-face management (k=0.34--0.47, fair-moderate).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Intervention: TDS referrals\                  108 lesions referred via TDS.                                                                                                                                                                           HP diagnosis for 36 lesions (33%). 2 MMs and 5 non-melanoma skin cancers.                                                                                                                                                                                                                                                                                                                                                                       Agreement TDS vs HP diagnosis k=0.41--0.63 (moderate). TDS consultations with good image quality had better agreement of TDS vs HP diagnosis (k=0.53--1.0, moderate-almost perfect).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  (108)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summarised results of the included survey-based studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         Summary                                                                                                                                   Population studied (N)   Outcomes
  ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Survey-based studies                                                                                                                                                                             

  Chappuis *et al* [@R38]       Survey of PCPs in 3 regions of France.                                                                                                    PCPs\                    Among dermoscopy users, 21 (54%) had no training, 8 (21%) trained via books, 5 (13%) trained with dermatologist, 2 (5%) trained online. Lower referral rates in dermoscopy group.\
                                                                                                                                                                          (425)                    Male PCPs significantly more likely to use a dermatoscope (p=0.001). PCPs \>50 significantly more likely to use a dermoscopy (p\<0.001). 30 (8%) had dermatoscope available, 16 (52%) used it \>1×/week.

  Morris *et al* [@R39]         Descriptive cross-sectional survey of US physicians (medical doctors and doctors of osteopathy) to examine dermoscopy use and barriers.   Family physicians\       Confidence recognising malignant lesions: not confident=2.1%, a little confident=18.8%, moderate=21.9%, confident=47.7%, very confident=9.4%.\
                                                                                                                                                                          (705)                    Currently using a dermatoscope associated with seeing \>400 patients/month and \>60 years.\
                                                                                                                                                                                                   Number of patients per month with suspicious lesions: \<1.5 lesions=12.2%, 1.5--4.99 lesions=19.6%, 5--9.99 lesions=19.2%, 10--19.99 lesions=23.1%, \>20 lesions=26%.\
                                                                                                                                                                                                   Used a dermatoscope=19.5%. Currently use a dermatoscope=8.3%. Intention to start using in 12 months=63.6%.

  Morris *et al* [@R40]         Same study but including all clinicians.                                                                                                  Physicians\              211 (14.6%) had used dermoscopy, 87 (6.0% of 1445) currently using, 656 (51.8%) intended to use in next 12 months. Use of and intention to use dermoscopy were associated with graduating recently, being a family physician, seeing a higher number of patients with cancer and being more confident differentiating malignant and benign skin lesions.
                                                                                                                                                                          (1466)                   

  Stratton and Loescher[@R42]   Online survey, acceptance of mobile teledermoscopy by nurse PCPs in Arizona, USA.                                                         Nurse practitioners\     Practitioners 40--60 years and been in practice for 1--15 years scored higher for intention to use mobile teledermoscopy. Few nurse practitioners used mobile teledermoscopy. They scored highly for perceiving that mobile teledermoscopy would have a positive impact on their practice, they would find it interesting to use, they could easily learn mobile teledermoscopy, it would help with rapid diagnosis of skin cancer and would improve the diagnosis of their patients, and they would use mobile teledermoscopy if they received training.
                                                                                                                                                                          (62)                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ABCD, Area, Border, Colour, Diameter; AC Rule, Asymmetry, Colour variation; AK, actinic keratosis; AUC, area under the curve; BCC, basal cell carcinoma; BLINCK, Benign, Lonely, Irregular, Nervous, Change, Known clues; DA, diagnostic accuracy; GP, general practitioner; HP, histopathology; MM, malignant melanoma; NPV, negative predictive value; NS, not significant; OR, Odds Ratio; 3PCL, 3-point checklist;PCP, primary care physician; PPV, positive predictive value; PSL, pigmented skin lesion; RCT, randomised controlled trial; SCARD, Skin Cancer Audit Research Database; SCC, squamous cell carcinoma; SDDI, short-term sequential digital dermoscopy imaging; SIT, sequential intervention trial; TADA, triage amalgamated dermoscopic algorithm; TDS, teledermoscopy; malig, malignant; sens, sensitivity; spec, specificity; susp, suspicious.

Most of the studies were non-RCT diagnostic accuracy studies. These showed increased diagnostic accuracy with the use of dermoscopy in primary care[@R28] or in teledermoscopy-based referral systems.[@R34] Some studies suggested this was due to improved ability to identify benign lesions when using a dermatoscope.[@R27] All studies that assessed the effect of training found that it improved diagnostic accuracy compared with minimal or no training.[@R25] There was evidence that use of dermoscopy without training displayed similar diagnostic accuracy to naked-eye examination.[@R33] Menzies *et al* [@R29] showed that a dermoscopy-related technology, SolarScan, had higher sensitivity than PCPs, although this was a non-significant finding.

[Table 4](#T6){ref-type="table"} summarises findings from the studies which investigated barriers and facilitators to implementing dermoscopy in primary care. Training requirements, cost of equipment and the time taken to perform dermoscopy were the most important barriers identified from the studies. However, for each barrier there were some papers that described it as a facilitator instead. Three papers performed cost-effective analyses of dermoscopy[@R24] and teledermoscopy,[@R26] and none found a significant cost-effective advantage. The main facilitators identified to the use of dermoscopy in primary care were reduced referrals, early detection of melanoma, and reduced patient and physician anxiety.

###### 

Barriers and facilitators to implementation of dermoscopy and teledermoscopy

  Aspect                                                    Quoted as barrier in:            Type of study                Quoted as facilitator in:   Type of study
  --------------------------------------------------------- -------------------------------- ---------------------------- --------------------------- ---------------
  Training requirements                                     Chappuis *et al* [@R38]          Survey                       Pagnanelli *et al* [@R30]   DA study
  Morris *et al* [@R40]                                     Survey                                                                                    
  van der Heijden *et al* [@R37]                            Cohort study                                                                              
  Cost\*                                                    Chappuis *et al* [@R38]          Survey                       Koelink *et al* [@R24]\*    RCT
  Morris *et al* [@R39]                                     Survey                           Rosendahl *et al* [@R25]     Cohort study                
  Moreno-Ramirez *et al* [@R36]                             DA study                         Ferrándiz *et al* [@R26]\*   RCT                         
  Livingstone and Solomon[@R41]\*                           Case series                                                                               
  Time consumption                                          Chappuis *et al* [@R38]          Survey                       Börve *et al* [@R34]        Case--control
  Moreno-Ramirez *et al* [@R36]                             DA study                                                                                  
  van der Heijden *et al* [@R37]                            Cohort study                                                                              
  Reimbursement for offering dermoscopy services (in USA)   Morris *et al* [@R39]            Survey                                                    
  Equipment issues                                          van der Heijden *et al* [@R37]   Cohort study                 Börve *et al* [@R34]        Case--control
  Moreno-Ramirez *et al* [@R36]                             DA study                                                                                  
  Reduced referrals                                                                                                       Chappuis *et al* [@R38]     Survey
  Koelink *et al* [@R24]                                    RCT                                                                                       
  Börve *et al* [@R34]                                      DA study                                                                                  
  Moreno-Ramirez *et al* [@R36]                             DA study                                                                                  
  Early detection of melanoma                                                                                             Chappuis *et al* [@R38]     Survey
  Reduced patient anxiety                                                                                                 Chappuis *et al* [@R38]     Survey
  Reduced physician anxiety                                                                                               Chappuis *et al* [@R38]     Survey
  Moreno-Ramirez *et al* [@R36]                             DA study                                                                                  
  Menzies *et al* [@R14]                                    DA study                                                                                  

\*Based on studies where a cost-effective analysis was undertaken.

DA, diagnostic accuracy; RCT, randomised controlled trial.

Patient and PCP attitudes and acceptance of dermoscopy {#s3-1}
------------------------------------------------------

Several papers assessed PCP attitudes to dermoscopy through questionnaires. Stratton and Loescher[@R42] found that nurse practitioners in the USA did not widely use dermatoscopes; however, they thought that dermoscopy would have a positive impact and would be willing to use mobile teledermoscopy if they received training. Morris *et al* [@R39] found that dermoscopy use among US physicians and doctors of osteopathic medicine was associated with seeing higher numbers of patients and with higher confidence in diagnosing skin lesions. Chappuis *et al* [@R38] found that dermoscopy use among French general practitioners (GPs) was associated with being older and male, and that only 8% of respondents had access to a dermatoscope. Livingstone and Solomon's[@R41] survey was the only one that assessed patient acceptability; they reported that 97% of patients from one general practice in Greater London were satisfied with the teledermoscopy service and 100% would recommend it.

Discussion {#s4}
==========

Principal findings {#s4-1}
------------------

Only a small number of studies have examined the use of dermoscopy or dermoscopy-related technologies in the primary care setting. These studies were all set in Europe, the USA and Australia, and due to their heterogeneous nature we were not able to synthesise the findings. Nevertheless, our review found that, with appropriate training, dermoscopy in primary care is more accurate than naked-eye examination, with improvements in sensitivity and specificity and number needed to excise. Furthermore, there was some evidence that teledermoscopy-based referral systems improve triage accuracy compared with paper-based or macroscopic image-based referral systems. The limited evidence did not show a significant cost-effectiveness benefit for either dermoscopy or teledermoscopy, although dermoscopy appears to lead to a reduction in unnecessary referrals and excisions. Importantly, the review also suggests that PCPs are receptive to incorporating dermoscopy into their routine practice, although they recognised ongoing implementation barriers, particularly around training, time requirements and technology costs.

Comparison with other studies {#s4-2}
-----------------------------

Our review suggests that dermoscopy in primary care is more accurate than naked-eye examination, supporting the findings from a previous review of dermoscopy for melanoma detection specifically in primary care published in 2012.[@R45] A recently published Cochrane review of dermoscopy for the diagnosis of melanoma has also concluded that, although data to support dermoscopy use in primary care are limited, 'it may assist in triaging suspicious lesions for urgent referral when employed by suitably trained clinicians'.[@R19] Our review also suggests that training PCPs in dermoscopy improves diagnostic accuracy. Again, this finding is supported by the recent Cochrane review which also suggests that 'formal algorithms may be of most use for dermoscopy training purposes and for less expert observers, however reliable data comparing approaches using dermoscopy in-person are lacking'.[@R19] Previous reviews have shown that using dermoscopy without training was no more accurate than naked-eye examination alone.[@R13] However, we were not able to identify the optimal length of training needed to train PCPs to use dermoscopy accurately, although studies of the effect of training on dermatologist diagnostic performance have shown improvement after between 2 days (6 hours of training per day)[@R46] and 10 weeks (comprising 6 workshops of 4--6 hours).[@R47] PCPs are likely to need short training courses, preferably with regular updates, as one of the few RCTs examining the impact of dermoscopy on the management of pigmented lesions in primary care reported a high dropout rate of GPs from the 20 hours of online trainingrequired for that study.[@R14]

It is important to note that the performance of dermoscopy in specialist clinics is not directly translatable as evidence for the performance of dermoscopy in primary care settings. A spectrum effect or spectrum bias is often observed when tests developed in one population are then used on another population. For example, the secondary care population is a referred population and has a higher prevalence of the condition being tested than primary care populations. This means that a diagnostic test, such as dermoscopy, will perform differently in the primary care population with the lower prevalence of the condition, compared with the secondary care population.[@R48] The direction of effect is not consistent across tests and conditions; hence, to establish the performance of tests among the non-referred population in primary care, they need to be evaluated in a primary care population. This review has therefore aimed to examine existing evidence for dermoscopy use in primary care settings.

Our review suggests that a range of PCPs, including nurse practitioners in the USA, and PCPs in the USA and France, hold positive views about incorporating dermoscopy into their routine practice. Evidence from Australia supports these views and demonstrates that a wide range of PCPs are able to incorporate dermoscopy into their routine clinical practice.[@R16] Only a small number of cost-effectiveness studies met our review criteria. They all assessed dermoscopy and teledermoscopy from a healthcare perspective, and only reported on short-term costs resulting from dermoscopy or non-dermoscopy approaches. None reported a significant cost-effectiveness benefit for dermoscopy[@R24] or teledermoscopy,[@R26] in the primary care setting, although they recommended the technologies as potentially useful tools. An English RCT of another diagnostic aid (MoleMate, incorporating SIAscopy) in primary care[@R49] also reported equivocal findings on cost-effectiveness, as the device, similar in accuracy to systematic application of the 7-point checklist, resulted in increased referrals from primary care.[@R49]

Interestingly, no papers reporting the use of dermoscopy smartphone applications ('apps') for automated diagnosis of melanoma or skin cancers in the primary care setting met the review inclusion criteria. Kassianos *et al* [@R51] reviewed 39 smartphone applications and found little evidence of clinical or research-based input into the design or evaluation of these apps. A recent editorial in *The* *Lancet Oncology* supported this finding,[@R52] and urged caution with early adoption of new technologies that are often poorly designed and untested, stressing the need to ensure that these technologies are appropriate, cost-effective and do not compromise patient safety. Recent studies have tested the application of artificial intelligence, neural networks and machine learning to the diagnosis of skin lesions; however, they have not yet been assessed in primary care settings.

Strengths, limitations and future research {#s4-3}
------------------------------------------

Our review examines the evidence for dermoscopy use in the primary care setting. It builds on the recent Cochrane review which explicitly reviewed evidence only about diagnostic accuracy of dermoscopy, with and without naked-eye examination, and describes this in specialist and generalist settings.[@R19] We therefore included studies with a range of methods, surveys and qualitative studies, as well as RCTs and diagnostic accuracy studies, but still only identified a relatively small number of publications. Unfortunately, we were unable to perform a meta-analysis due to the heterogeneity in study designs, settings, populations and outcomes. All the studies are from high-income countries and therefore may be less generalisable to other countries with different healthcare systems.

Conclusions {#s5}
===========

Despite the limited evidence, this review provides moderate support for the use of dermoscopy in primary care, with the weight of the available evidence pointing to a benefit in diagnostic accuracy for managing suspicious skin lesions. Dermoscopy is acceptable to PCPs, so it could help them triage suspicious lesions for urgent referral or reassurance. However, it will be important to establish further evidence on minimum for training to reach competence, as well as the cost-effectiveness and patient acceptability of implementing dermoscopy in primary care.
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